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a b s t r a c t
Inﬂuenza A viruses pose a serious threat to public health. Current inﬂuenza A vaccines predominantly
focus on hemagglutinin (HA) and show strain-speciﬁc protection. Neuraminidase (NA) is much less
studied in the context of humoral immunity against inﬂuenza A viruses. The purpose of this study is to
evaluate the cross protective immunity of NA presented on Lactococcus lactis (L.lactis) surface against
homologous and heterologous inﬂuenza A viruses in the mouse model. L.lactis/pNZ8110-pgsA-NA was
constructed in which pgsA was used as an anchor protein. Mice vaccinated orally with L.lactis/pNZ8110-
pgsA-NA could elicit signiﬁcant NA-speciﬁc serum IgG and mucosa IgA antibodies, as well as
neuraminidase inhibition (NI) titers. Importantly, L.lactis/pNZ8110-pgsA-NA provided 80% protection
against H5N1, 60% protection against H3N2 and H1N1, respectively. These ﬁndings suggest that
recombinant L.lactis/pNZ110-pgsA-NA in the absence of adjuvant via oral administration can be served
as an effective vaccine candidate against diverse strains of inﬂuenza A viruses.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza A viruses, including H5N1, H3N2 and H1N1 subtypes,
pose a potential pandemic threat to public health (Subbarao and
Joseph, 2007). According to World Health Organization (WHO)'s
statistics, as of January 2014, there have been a total of 650 conﬁrmed
human cases of H5N1 virus, with 386 deaths (59%mortality rate) in 15
countries since 2003. (Available online: http://www.who.int/inﬂuenza/
human_animal_interface/EN_GIP_20131008CumulativeNumberH5N1
cases.pdf). In the event that an H5N1 strain gains the ability to spread
efﬁciently from human to human, the lack of subtype-speciﬁc
immunity would make the human population highly vulnerable. In
addition, currently licensed seasonal inﬂuenza vaccines are designed
to protect humans from the prevailing strains of human inﬂuenza A
lineages H1N1 and H3N2 and of inﬂuenza B virus. These vaccines'
principal target is the most abundant viral surface antigen, hemagglu-
tinin (HA), which anti-HA antibodies are often neutralizing, and are
used routinely to assess vaccine immunogenicity (Wohlbold and
Krammer, 2014).
Neuraminidase (NA) is the secondmost abundant inﬂuenza surface
glycoprotein and contributes to virus replication in several ways, most
notably by removing sialic acids from the host and viral glycoproteins,
releasing newly formed virus particles from infected cells (Lakdawala
et al., 2011; Matrosovich et al., 2004; Palese et al., 1974). Although NA
antibodies do not prevent attachment and entry of inﬂuenza virus into
cells, they sharply limit virus spread (Kilbourne et al., 1968) and
thereby contribute to immunity against inﬂuenza virus (Clements
et al., 1986). NA-speciﬁc immunity has been reported to reduce the
severity of clinical illness and viral shedding among infected persons
(Marcelin et al., 2011; Murphy et al., 1972). Further, a mouse mono-
clonal antibody (MAb) speciﬁc for H5N1 viral NA has therapeutic
beneﬁt against H5N1 infection in mice and ferrets (Shoji et al., 2011).
In addition, the NAs of currently circulating H5N1 viruses and human
H1N1 viruses are classiﬁed in the same NA subtype and low levels of
anti-NA cross-reactive antibodies to H5N1 viruses have been detected
in human sera of unexposed humans (Lu et al., 2014). However, there
have been no attempts to investigate cross-protective immunity of the
NA as a novel universal vaccine against inﬂuenza H5N1, H3N2 and
H1N1 viruses.
It has been demonstrated that Lactococcus lactis (L.lactis) is an
ideal vaccine delivery vector and has been engineered to express
many viral antigens (Pontes et al., 2011; Wells and Mercenier,
2008). Our previous studies have shown that L.lactis, expressing
hemaglutinin (HA) from A/chicken/Henan/12/2004(H5N1) and
then coated by enteric capsule, is a safe and effective vaccine
against homologous H5N1 virus infection in mice (Lei et al., 2010).
Similarly, we also described that HA1 from A/chicken/Henan/12/
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2004(H5N1) virus was displayed on the surface of L.lactis in which
pgsAwas used as an anchor protein, and showed it to be protective
against homologous H5N1 virus by oral co-administration with
CTB in mice (Lei et al., 2011). Recently, it also showed that
intranasal immunization of L.lactis-HA combined with mucosal
adjuvant LTB could provide complete protection against homo-
logous H5N1 in chickens (Lei et al., 2014). However, these vaccines
focus on raising humoral responses against HA, it remains largely
unknown regarding the immunogenicity of NA presented on
L.lactis surface in the absence of mucosal adjuvant via oral
administration in the mouse model.
We hypothesized that NA presented on L.lactis surface could
provide cross protective immunity against homologous and het-
erologous inﬂuenza A viruses. To address this hypothesis, NA gene
derived from A/Vietnam/1203/2004 (H5N1) (VN/1203/04) was
designed to express on the surface of L.lactis, in which pgsA was
used as an anchor protein (Lei et al., 2011). The immunogenicity of
L.lactis/pNZ110-pgsA-NA was then evaluated via oral administra-
tion without the use of adjuvant in the mouse model. This study
reported here suggests that L.lactis/pNZ110-pgsA-NA can induce
signiﬁcant humoral and mucosal antibodies to protect mice
against homologous H5N1, heterologous H3N2 or H1N1 virus
challenge. Further, these ﬁndings support that NA presented on
L.lactis surface can be considered an alternative approach to
develop a universal vaccine against inﬂuenza A viruses.
Results
Expression of NA protein on L.lactis
Recombinant pNZ8110-pgsA-NA plasmid expressing NA gene of A/
Vietnam/1203/2004 (H5N1) was constructed (Fig. 1A). Further, expres-
sion of NA protein on L.lactis NZ9000 was detected by western blotting
using anti-NA monoclonal antibody (Fig. 1B). As we expected, there is
no band shown in the L.lactis/pNZ8110-pgsA control cells, while a
speciﬁc band was observed at expected size for pgsA-NA fusion protein
(approximately 100 kDa) (Fig. 1B, Lane 2) in the L.lactis/pNZ8110-pgsA-
NA cells.
To determine whether NA protein was expressed on the surface
of L.lacti, L.lactis/pNZ8110-pgsA-NA was incubated with mouse
anti-NA monoclonal antibody for binding, and followed by FITC
conjugated goat anti-mouse IgG and then detected by immuno-
ﬂuorescence assay and ﬂow cytometry (FACS) analysis. L.lactis/
pNZ8110-pgsA-NA showed a higher speciﬁc and positive signal
than L.lactis/pNZ8110-pgsA control (Fig. 1C and D). These results
demonstrate NA protein is located on the surface of L.lactis.
Immune responses elicited d by oral administration of L.lactis/
pNZ8110-pgsA-NA
At day 17 and day 37 after the ﬁrst immunization, sera samples
were obtained from all mice to screen for antibody responses as a
marker of immunogenicity. There was no signiﬁcant serum IgG
detected in the saline, L.lactis/pNZ8110-pgsA and L.lactis/pNZ8110-
pgsA-NA groups at day 17 after the ﬁrst immunization. However,
mice administered orally with L.lactis/pNZ8110-pgsA-NA could
elicit a higher signiﬁcant NA-speciﬁc IgG titer than saline or
L.lactis/pNZ8110-pgsA group at day 37 after the ﬁrst immuniza-
tion, (Fig. 2A).
To assess whether L.lactis/pNZ8110-pgsA-NA could induce the
mucosal immune responses, intestinal and upper respiratory
washes were collected at day 17 and day 37 after the ﬁrst
immunization. As shown in Fig. 2C and D, there was no signiﬁcant
IgA produced in all groups at day 17. Whereas, L.lactis/pNZ8110-
pgsA-NA induced signiﬁcantly detectable levels of NA-speciﬁc
mucosal IgA compared to saline or L.lactis/pNZ8110-pgsA group
at day 37 in the intestinal and upper respiratory washes.
These data indicate that mice vaccinated orally with L.lactis/
pNZ8110-pgsA-NA after prime-boost immunization can result in
signiﬁcant serum IgG and mucosal IgA levels which may contri-
bute to protection against virus infection.
Neuraminidase inhibition (NI) titers induced by L.lactis/pNZ8110-
pgsA-NA
The sera isolated from the vaccinated mice were detected by NI
assay. As shown in Fig. 2B, there were no signiﬁcant NI titers of all
groups detected at day 17. However, the NI titers in the L.lactis/
pNZ8110-pgsA-NA group could be signiﬁcantly detected compared
to saline or L.lactis/pNZ8110-pgsA group at day 37. These data are
consistent with ELIA assay, mice vaccinated orally with L.lactis/
pNZ8110-pgsA-NA after the boost immunization could produce a
higher NA-speciﬁc IgG antibody and also elicit signiﬁcant NI titers
which may prevent virus infection.
Cross protective immunity against virus challenge
At two weeks after the last immunization, all mice were
challenged by intranasal inoculation with 20 ml of 104 TCID50 of
A/Vietnam/1203/2004(H5N1), A/Hong Kong/1/1968 (H3N2) or
A/California/04/2009(H1N1) virus. The control groups that
received saline or L.lactis/pNZ8110-pgsA experienced substantial
weight loss beginning at day 2 post challenge, a high level of lung
virus titer and death by 6 to 8 days post infection. In contrast, mice
immunized orally with L.lactis/pNZ8110-pgsA survived 80% against
H5N1 challenge, 60% against H3N2 and H1N1 virus challenge,
respectively. Further, these survived mice showed slight loss of
body weight and a lower virus titer in the lung (Fig. 3). Taken
together, these results provide evidence that L.lactis/pNZ8110-
pgsA-NA is a safe and effective immunogen to induce cross
protective immunity against homologous H5N1 and heterologous
H3N2 and H1N1 in mice.
Discussion
Most of the current approaches to vaccine design focus on
measuring the antibody response to inﬂuenza A HA, the predomi-
nant homotrimeric glycoprotein located on the surface of the virus
(Wohlbold and Krammer, 2014). In the scope of inﬂuenza virus
research, relatively little attention is given to the NA, and while the
use of NA as a vaccine antigen is studied by only a small pocket of
investigators, recent evidence has reignited interest in the potential
use of NA in vaccine design as well as the ability of NA-directed
antibodies to confer protection against a range of inﬂuenza virus
subtypes (Marcelin et al., 2012). Indeed, the possibility of NA-based
protection has been recognized by the international vaccine com-
munity, and the proposal to somehow standardize the amount of NA
in vaccine formulations has been entertained at past WHO confer-
ences on inﬂuenza virus vaccine development (Bright et al., 2009;
Eichelberger et al., 2008). More recently, one group identiﬁed a
universally conserved NA peptide sequence (222–230: I–L–R–T–Q–
E–S–E/S–C) that is 100% conserved in all inﬂuenza A virus subtypes
as well as in the NAs of inﬂuenza B strains, and conferred cross
protection against diverse strains of inﬂuenza viruses (Doyle et al.,
2013). Thus, NA offers the potential for the development for a new
novel universal inﬂuenza vaccine.
Understandably, the induction of mucosal immunity via mucosal
administration (oral or intranasal) is necessary to ensure protection
against multiple subtypes of inﬂuenza A virus. Secretion of IgA is a
representative antibody of mucosal immune response, and confers
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efﬁcient protection against acquired mucosal infection (Wells and
Mercenier, 2008). Furthermore, antigen presented on L.lactis surface
is more immunogenic, and easier to recognize by immune system
(Lei et al., 2011; Wells and Mercenier, 2008). We have shown
previously that L.lactis is an ideal mucosal vehicle for inﬂuenza
vaccine inducing signiﬁcant humoral IgG and mucosal IgA anti-
bodies against homologous H5N1 virus infection in the mouse or
chicken model (Lei et al., 2010, 2011, 2014). However, little is known
regarding the immunogenicity of NA presented on L.lactis surface,
since NA is another major glycoprotein on the surface of the virus
and has historically served as the target for antiviral drug therapy
and is much less studied in the context of humoral immunity
against divergent inﬂuenza A viruses (Wohlbold and Krammer,
2014). Based on this knowledge, we identiﬁed NA presented on
L.lactis surface by immunoﬂuorescence assay and ﬂow cytometric
analysis (Fig. 1C and D) in which pgsA was used as an anchor
protein displaying HA1 protein of H5N1 virus, as described pre-
viously (Lei et al., 2011) and investigated its immunogenicity after
optimizing the schedule and dosage for oral administration com-
pared with our previous studies (Lei et al., 2011).
It is generally accepted that anti-NA antibodies are thought to be
non-neutralizing, but the well-established role for NA antibodies is to
provide a reduction in virus replication (Chen et al., 2012). In this
study, anti-NA antibodies induced by L.lactis/pNZ8110-pgsA-NA were
determined by ELISA and NI assay, respectively. It was shown that
L.lactis/pNZ8110-pgsA-NA could elicit signiﬁcant serum IgG and
mucosal IgA antibodies responses, as well as NI titers which may
contribute to reducing virus replication. Interestingly, we determined
virus titer in the lung of mice vaccinated orally with L.lactis/pNZ8110-
pgsA-NA after virus challenge, and discovered that antibodies to NA
did positively correlate with virus shedding in lung. Consistent with a
recent report showing that antibodies against NA playing crucial
roles during viral replication (Doyle et al., 2013), our study demon-
strated that the cross-reactivity of L.lactis/pNZ8110-pgsA-NA induced
NA antisera to divergent inﬂuenza A viruses limited virus spread,
thus supporting this idea.
The development of a universal inﬂuenza A vaccine is one of the
major goals in global pandemic preparedness plans. The current
strategy for designing a universal inﬂuenza vaccine aims to skew
the humoral immune response (Wohlbold and Krammer, 2014). In
this case, NA antibodies also contribute to cross-protective immu-
nity against inﬂuenza A viruses. In our studies, L.lactis/pNZ8110-
pgsA-NA conferred 80% protection against homologous H5N1, and
60% protection against H3N2 and H1N1, respectively. Although
pNis Promoter     
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Fig. 1. Expression of NA displayed on L.lactis surface. (A) Schematic diagram of L.lactis/pNZ8110-pgsA-NA. A GS linker inserted between pgsA and NA to stabilize the NA
protein expression. (B) Western blot analysis. Lane 1: L.lactis/pNZ8110-pgsA; Lane 2: L.lactis/pNZ8110-pgsA-NA. (C) Immunoﬂuorescence microscopy assay of NA protein.
L.lactis/pNZ8110-pgsA (left) and L.lactis/pNZ8110-pgsA-NA (right) (magniﬁcation: 1000 ). (D) Flow cytometric analysis of NA display on L.lactis surface. L.lactis/pNZ8110-
pgsA (left) and L.lactis/pNZ8110-pgsA-NA (right; positive rate: 60.3%).
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L.lactis/pNZ8110-pgsA-NA did not confer 100% protective efﬁcacy
against homologous and heterologous inﬂuenza A viruses, this
study suggests ideal protection provided by L.lactis/pNZ8110-pgsA-
NA requires the coordinated efforts of enhancing its immunogeni-
city either which includes some combination of the NA and HA
antigen (Johansson and Cox, 2011), or combines with the use of the
mucosal adjuvant. Collectively, our ﬁndings agree with that NA is an
attractive antigen for developing a novel universal inﬂuenza
vaccine.
In conclusion, our ﬁndings strongly support oral administration
of mice with L.lactis/pNZ8110-pgsA-NA in the absence of adjuvant
can induce signiﬁcant humoral and mucosal immune responses, as
well as NI titers. Given the induction of cross-protective immunity
in the vaccinated mice, L.lactis/pNZ8110-pgsA-NA would likely
provide a signiﬁcant barrier to the spread of inﬂuenza A virus
and also be economically advantageous for inﬂuenza vaccine
development. Thus, L.lactis/pNZ8110-pgsA-NA may be a promising
candidate for a universal inﬂuenza vaccine.
Materials and methods
Construction of L.lactis vector
The NA gene (1459 bp) of A/Vietnam/1203/2004 (H5N1) was
PCR-ampliﬁed from pCDNA3.1-HA (kindly provided by St. Jude
Children's Research Hospital, Memphis, TN, USA) using the follow-
ing primers: NA-F: CTAGCTAGCGGTACCGCCGCCACCATGAA (Nhe I);
NA-R: CCGAATTCACAGGAAGTATTCAATC (EcoR I) and cloned into
pNZ8110-pgsA (Lei et al., 2011), the resulting plasmid pNZ8110-
pgsA-NA was transformed into competent L.lactis NZ9000, the
positive clone was named L.lactis/pNZ8110-pgsA-NA.
Western blotting
The expression level of NA protein was determined by Western
blot analysis as described previously (Lei et al., 2011). Brieﬂy, 108
cells of L.lactis/pNZ8110-pgsA-NA pellets were washed three times
Fig. 2. Immune responses in mice. Sera, intestine and upper respiratory washes were collected from mice vaccinated orally with saline, L.lactis/pNZ8110-pgsA or L.lactis/
pNZ8110-pgsA-NA at day 17 and day 37 after the ﬁrst immunization. (A) NA-speciﬁc IgG antibody responses in the sera (n¼16 mice/group). (B) NA-speciﬁc IgA antibody
responses in the intestine washes (n¼3 mice /group). (C) NA-speciﬁc IgA antibody responses in the upper respiratory washes (n¼3 mice/group). (D) NI titers (n¼16 mice/
group). The value less than 24 is considered no signiﬁcance. Data are represented as mean7SD. Asterisk indicates signiﬁcant difference, as compared to saline and L.lactis/
pNZ8110-pgsA controls (po0.05).
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with 500 ml of sterile saline, and then re-suspended with 50 ml of
6 loading buffer and boiled for 10 min. Treated samples were
run on SDS-polyacrylamide gel electrophoresis and then trans-
ferred to nitrocellulose membrane (Bio-rad, Hercules, California,
USA). After blocking with 5% skim milk at room temperature for
2 h, the membrane was incubated with a monoclonal mouse
anti-NA antibody (kindly provided by Beiresource, Manassas, VA,
USA). After incubated overnight at 4 1C, and then followed by
afﬁnity-puriﬁed horseradish peroxidase (HRP)-conjugated anti-
mouse IgG (Sigma-Aldrich Corporation, St. Louis, MO, USA). The
membrane was reacted with the West Pico Chemiluminescent
Substrate (Thermo Fisher Scientiﬁc Inc., Rockford, IL, USA) and
Fig. 3. Protection efﬁcacy against lethal challenge with different inﬂuenza A viruses in mice. The results are expressed in terms of percent body weight (A, B and C) (n¼10
mice/group), lung virus titer (D, E and F) (n¼3 mice/group) at day 5 post-infection and percent survival (G, H and I) (n¼10 mice/group). Two weeks after the last
immunization, mice were intranasally infected with 20 ml of 104 TCID50 of lethal dose of A/Vietnam/1203/2004(H5N1) (A, D and G), A/Hong Kong/1/1968 (H3N2) (B, E and H)
or A/California/04/2009(H1N1) (C, F and I). Data of weight changes and lung virus titers are represented as mean7SD. Asterisk indicates signiﬁcant difference, as compared
to saline and L.lactis/pNZ8110-pgsA controls (po0.05).
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imaged using Molecular Imager ChemiDoc XRS System (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). L.lactis/pNZ8110-pgs cells
were used as a negative control.
Immunoﬂuorescence assay and ﬂow cytometry analysis
NA protein displayed on the surface of L.lactis was analyzed by
immunoﬂuorescence assay (Leica DM4000B, Germany) and ﬂow
cytometry (FACS) analysis (BD FacsCalibur, BD Bioscience, San Jose,
CA, USA). Brieﬂy, 108 cells of L.lactis/pNZ8110-pgsA-NA were
washed three times with sterile saline containing 0.5% bovine
serum albumin (BSA) and then incubated with monoclonal mouse
anti-NA antibody at 4 1C for 1 h, followed by a FITC-conjugated
goat anti-mouse IgG at 4 1C for 30 min and re-suspended with
500 ml of sterile saline. Finally, L.lactis/pNZ8110-pgsA-NA cells
were used for immunoﬂuorescence assay and FACS analysis,
respectively. L.lactis/pNZ8110-pgsA cells were used as a negative
control.
Animal experiments and sample collection
Speciﬁc-pathogenic-free (SPF) six-week-old female BALB/c
mice were used (SLC Company, Shanghai, China) in this study.
The concentration of recombinant L.lactis/pNZ8110-pgsA-NA was
adjusted to 1012 colony forming unit (CFU)/ml with sterile saline.
Mice (16 mice/group) were immunized orally with 1012 CFU of
L.lactis/pNZ8110-pgsA-NA at day 0, 1, 2, 3 and boosted at day 20,
21, 22, 23. In the meantime, L.lactis/pNZ8110-pgsA and saline were
used as controls. Sera, intestinal and upper respiratory washes
were obtained at day 17 and day 37 after the ﬁrst immunization.
At two weeks after the last immunization, all vaccinated mice
were lightly anesthetized with CO2 and inoculated intranasally
with 20 ml of 104 EID50 of A/Vietnam/1203/2004 (H5N1), A/Hong
Kong/1/1968 (H3N2) or A/California/04/2009(H1N1). Mice were
observed for illness, weight loss, and death for 14 days after virus
infection. Lung virus titer was determined.
Lungs from vaccinated mice were harvested at day 5 post-
infection. Tissue samples were homogenized and processed as
described previously (Boon et al., 2010). The titer of virus in each
sample was calculated by the Reed and Muench method (Reed and
Muench, 1938) and expressed as 50% tissue culture infective dose
(TCID50).
All animal experiments were carried out in accordance with the
Guideline for Animal Experiment prescribed and approved by an
Institutional Animal Care and Use Committee (IACUC) of Nanchang
University. Virus challenge experiments must be strictly per-
formed under the enhanced bio-safety level-3 laboratory (BSL-3).
Enzyme-linked immunosorbent assay (ELISA)
Immune sera from the vaccinated mice were collected by
bleeding from posterior orbital venous plexus at day 17 and day
37. NA-speciﬁc immunoglobulin G (IgG) and secretory immuno-
globulin A (IgA) antibodies were detected by enzyme-linked
immunosorbent assay (ELISA) using recombinant NA protein of
A/Vietnam/1203/2004 (H5N1) as a coating antigen as described
Fig. 3. (continued)
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previously (Lei et al., 2010). ELISA end point titers were expressed
as the highest dilution that yielded an optical density greater than
twice the mean plus one standard deviation of that of similarly
diluted negative control samples.
Neuraminidase inhibition (NI) assay
A miniaturized format of the conventional NI assay was applied
to detect the NA speciﬁc antibody titers (Sandbulte et al., 2009).
Brieﬂy, 50 μl of mice sera from each group was taken at 2-fold
serial dilutions in a 96-well micro-titer plate. 50 μl of puriﬁed rNA
(0.25 mg/ml) (kindly provided by Beiresource, Manassas, VA, USA)
was added to each well and incubated at 37 1C for 2 h. The
neuraminidase inhibition titer was represented as the highest
dilution until there was no neuraminidase activity observed.
Statistical analysis
Data are presented as the means7standard deviations (S.D.).
All analysis for statistically signiﬁcant differences was performed
by the Student t test and one-way ANOVA. A p value less than 0.05
was considered to be signiﬁcant.
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